Physician profile
Roderick Warren
NPI 1093719841
$296,385.05
in general payments reported to CMS, 2019-2025
66 companies · $66K in 2025
The $66K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66K · 2020: $34K · 2021: $43K · 2022: $25K · 2023: $19K · 2024: $43K · 2025: $66K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $86K · Food and Beverage: $18K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $16K · Consulting Fee: $5,055 · Travel and Lodging: $3,058 · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $85,514.50 |
| Food and Beverage | $18,196.71 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $15,582.50 |
| Consulting Fee | $5,055.00 |
| Travel and Lodging | $3,058.39 |
| Education | $276.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $51,651.72 | 2019-2025 | Ubrelvy, Qulipta, Botox |
| Lilly USA, LLC | $48,236.15 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Biogen, INC. | $35,382.27 | 2019-2025 | Vumerity, Tysabri |
| Amgen INC. | $35,340.14 | 2019-2025 | Uplizna |
| Eisai INC. | $26,966.23 | 2020-2025 | |
| Tg Therapeutics, INC. | $16,967.10 | 2023-2025 | |
| Pfizer INC. | $11,841.34 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $11,575.68 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Alexion Pharmaceuticals, INC. | $10,295.10 | 2019-2025 | Ultomiris |
| Allergan, INC. | $9,609.41 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $9,295.00 | 2021 | |
| Genzyme Corporation | $7,149.87 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $5,567.29 | 2022 | |
| Livanova USA, INC. | $2,689.23 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Emd Serono, INC. | $1,690.99 | 2019-2025 | Mavenclad |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,123.57 | 2019-2025 | |
| Vanda Pharmaceuticals INC. | $887.07 | 2025 | Ponvory |
| Ucb, INC. | $769.07 | 2019-2025 | Briviact, Rystiggo, Zilbrysq |
| Supernus Pharmaceuticals, INC. | $607.49 | 2019-2025 | Qelbree |
| Avanir Pharmaceuticals, INC. | $526.37 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $502.97 | 2022-2025 | Fycompa, Firdapse |
| Sk Life Science, INC. | $469.07 | 2020-2025 | |
| Lundbeck LLC | $463.01 | 2019-2025 | Vyepti, Rexulti |
| Neurocrine Biosciences, INC. | $442.51 | 2019-2025 | Ingrezza, Ongentys |
| Mdd US Operations, LLC | $441.47 | 2019-2025 | Gocovri, Gocovri |
| Genentech USA, INC. | $412.58 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Evrysdi |
| Jazz Pharmaceuticals INC. | $409.63 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $397.91 | 2019-2022 | |
| Neurelis, INC. | $386.09 | 2021-2025 | Valtoco |
| Acadia Pharmaceuticals INC | $361.04 | 2019-2025 | Nuplazid, Daybue |
| Csl Behring | $324.71 | 2019-2025 | Hizentra |
| Celgene Corporation | $288.29 | 2021-2025 | Zeposia |
| Argenx US, INC. | $275.59 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Mallinckrodt Hospital Products INC. | $243.23 | 2020-2025 | Acthar |
| Ceribell, INC. | $243.17 | 2022 | |
| Amneal Pharmaceuticals LLC | $237.92 | 2019-2025 | Rytary, Crexont |
| Janssen Pharmaceuticals, INC | $223.91 | 2020-2022 | |
| Tanabe Pharma America, INC. | $201.77 | 2019-2025 | Radicava |
| Kyowa Kirin, INC. | $198.07 | 2019-2023 | Nourianz |
| Acorda Therapeutics, INC | $193.58 | 2019-2023 | Inbrija |
| Otsuka America Pharmaceutical, INC. | $154.16 | 2023-2025 | Rexulti, Nuedexta |
| Banner Life Sciences, LLC | $149.15 | 2021-2024 | |
| Horizon Therapeutics Plc | $132.69 | 2023 | Uplizna |
| E.R. Squibb & Sons, L.L.C. | $120.83 | 2020-2025 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $112.45 | 2019-2024 | Hyqvia |
| Sumitomo Pharma America, INC. | $104.61 | 2023-2024 | Aptiom |
| Grifols USA, LLC | $90.87 | 2019-2023 | Gamunex-C |
| Upsher-Smith Laboratories LLC | $88.84 | 2020-2023 | |
| Adamas Pharmaceuticals, INC. | $81.40 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $64.83 | 2023-2024 | Purified Cortrophin Gel |
| Zyla Life Sciences, INC. | $50.92 | 2019 | |
| Shire North American Group INC | $44.43 | 2019 | |
| Scilex Pharmaceuticals INC. | $39.64 | 2024 | |
| Alnylam Pharmaceuticals INC. | $33.70 | 2022 | |
| Ironshore Pharmaceuticals INC. | $31.67 | 2019 | |
| Amylyx Pharmaceuticals, INC. | $30.75 | 2023 | Relyvrio |
| Merck Sharp & Dohme LLC | $26.27 | 2021-2022 | |
| Nevro Corp. | $21.01 | 2023 | Senza |
| Servier Pharmaceuticals LLC | $18.58 | 2025 | |
| Cycle Pharmaceuticals INC | $18.28 | 2025 | Tascenso Odt, Bafiertam |
| Assertio Therapeutics, INC. | $16.60 | 2020 | |
| Akcea Therapeutics, INC. | $14.85 | 2021 | |
| Merz North America, INC. | $13.46 | 2019 | |
| Covidien Lp | $12.92 | 2020 | |
| Medtronic USA, INC. | $12.58 | 2019 | |
| Currax Pharmaceuticals LLC | $11.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roderick Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.